A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Trial Profile

A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Asciminib (Primary) ; Bosutinib
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 02 Aug 2017 Planned End Date changed from 29 Feb 2024 to 22 Mar 2024.
    • 02 Aug 2017 Planned primary completion date changed from 29 Feb 2024 to 22 Mar 2024.
    • 02 Aug 2017 Planned initiation date changed from 15 Aug 2017 to 6 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top